Could a cystic fibrosis drug help stroke patients?

NCT ID NCT05203224

Completed Disease control Sponsor: University of Melbourne Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether adding dornase alfa (a drug used for cystic fibrosis) to standard clot-busting treatment could improve blood flow before a clot removal procedure in people having a major stroke. 330 adults with acute ischemic stroke and a large vessel blockage were enrolled. The goal was to see if the drug helps dissolve clots faster and safely, to guide a future larger trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dornase alfa (also called DNase or Pulmozyme)
What this could lead to: If successful, this could lead to a new add-on treatment that helps restore blood flow faster in people having a major stroke, potentially reducing brain damage.
What could go wrong: This is an early Phase 2 trial with no control group, so results are preliminary. The drug may not improve outcomes or could increase bleeding risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC STROKE

Contacts and locations

Locations

Princess Alexandra Hospital

Brisbane, Queensland, 4102, Australia
Royal Adelaide Hospital

Adelaide, South Australia, 5000, Australia
Royal Melbourne Hospital

Melbourne, Victoria, 3050, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.